Kidney Function Change and All-Cause Mortality in Denosumab Users with and without Chronic Kidney Disease

Denosumab is approved for osteoporosis treatment in subjects with and without chronic kidney disease (CKD). Confirmation is required for its safety, treatment adherence, renal function effect, and mortality in patients with CKD. A retrospective cohort study was conducted to compare new users of deno...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ping-Hsun, Lin, Ming-Yen, Huang, Teng-Hui, Lee, Tien-Ching, Lin, Sung-Yen, Chen, Chung-Hwan, Kuo, Mei-Chuan, Chiu, Yi-Wen, Chang, Jer-Ming, Hwang, Shang-Jyh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875658/
https://www.ncbi.nlm.nih.gov/pubmed/35207673
http://dx.doi.org/10.3390/jpm12020185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875658/
https://www.ncbi.nlm.nih.gov/pubmed/35207673
http://dx.doi.org/10.3390/jpm12020185

Ejemplares similares